Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Chemokine Therapeutics Corp (CHKT) since 2008 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Chemokine Therapeutics Corp. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 1092959.
Total stock buying since 2008: $503,329.
Total stock sales since 2008: $4,269.
Total stock option exercises since 2008: $0.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2009 | 605,400 | $7,626 | 0 | $0 | 0 | $0 |
| 2008 | 3,604,166 | $495,703 | 45,650 | $4,269 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2009-01 | 605,400 | $7,626 | 0 | $0 | 0 | $0 |
| 2008-08 | 1,445,000 | $104,204 | 45,650 | $4,269 | 0 | $0 |
| 2008-06 | 746,666 | $111,999 | 0 | $0 | 0 | $0 |
| 2008-04 | 100,000 | $17,000 | 0 | $0 | 0 | $0 |
| 2008-02 | 1,312,500 | $262,500 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2009-01-15 | Salari Hassan (10% Owner) | Buy | 256,900 | .01 | 2,569 |
| 2009-01-12 | Salari Hassan (10% Owner) | Buy | 34,000 | .01 | 340 |
| 2009-01-09 | Salari Hassan (10% Owner) | Buy | 314,500 | .01 | 4,717 |
| 2008-08-27 | Salari Hassan (10% Owner) | Buy | 1,390,000 | .07 | 100,079 |
| 2008-08-25 | Evans Donald Rm (V.P. Corporate Communications) | Sale | 44,200 | .09 | 4,110 |
| 2008-08-22 | Evans Donald Rm (V.P. Corporate Communications) | Buy | 55,000 | .07 | 4,125 |
| 2008-08-22 | Evans Donald Rm (V.P. Corporate Communications) | Sale | 1,450 | .11 | 159 |
| 2008-06-13 | Kowalchuk George M (Director) | Buy | 666,666 | .15 | 99,999 |
| 2008-06-13 | Salari Hassan (Chief Scientific Officer) | Buy | 80,000 | .15 | 12,000 |
| 2008-04-16 | Salari Hassan (Chief Scientific Officer) | Buy | 50,000 | .18 | 9,000 |
| 2008-04-10 | Salari Hassan (Pres./Chief Scientific Officer) | Buy | 50,000 | .16 | 8,000 |
| 2008-02-07 | Bahadori Reza (Director) | Buy | 300,000 | .20 | 60,000 |
| 2008-02-07 | Byrd Bernard C Ii (Director) | Buy | 300,000 | .20 | 60,000 |
| 2008-02-07 | Kuhn Brian (Director) | Buy | 300,000 | .20 | 60,000 |
| 2008-02-07 | Korz Walter (Vice President, Drug Dev.) | Buy | 50,000 | .20 | 10,000 |
| 2008-02-07 | Salari Hassan (Pres./Chief Scientific Officer) | Buy | 312,500 | .20 | 62,500 |
| 2008-02-07 | Jaffer Bashir (Chief Financial Officer) | Buy | 50,000 | .20 | 10,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of CHKT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Chemokine Therapeutics Corp (symbol CHKT, CIK number 1092959) see the Securities and Exchange Commission (SEC) website.